<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200769</url>
  </required_header>
  <id_info>
    <org_study_id>2012_66</org_study_id>
    <secondary_id>2013-A01156-39</secondary_id>
    <nct_id>NCT03200769</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy</brief_title>
  <acronym>SASER</acronym>
  <official_title>Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant
      Epilepsy. The primary goal is to evaluate the efficacity after 3 months of obstructive sleep
      apnea syndrome treatment by CPAP on the epilepsy seizures frequency.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients from group IIa and IIb with decreased seizure frequency</measure>
    <time_frame>At 3 months</time_frame>
    <description>Decreased &gt; 50% after CPAP treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients from group IIa and IIb with decreased seizure frequency</measure>
    <time_frame>At 6 months ; At 12 months</time_frame>
    <description>Decreased &gt; 50% after CPAP treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients from group III with decreased seizure frequency</measure>
    <time_frame>At 3 months ; At 6 months ; At 12 months</time_frame>
    <description>Decreased &gt; 50% after CPAP treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of AHI on the number of night seizures</measure>
    <time_frame>At 12 months</time_frame>
    <description>Does the AHI has an impact on the number of night seizure?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the localisation and the type of epilepsy based on patient medical history exam (video-electroencephalogram) on the SAS risk</measure>
    <time_frame>At 12 months</time_frame>
    <description>Does the AHI is impacted by the localisation and the type of epilepsy?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seizures based on the seizures diary</measure>
    <time_frame>At 12 months</time_frame>
    <description>Impact of SAS treatment on the pharmacoresistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who became drug-susceptible based on the seizures diary</measure>
    <time_frame>At 3 months ; At 6 months ; At 12 months</time_frame>
    <description>Impact of SAS treatment on the pharmacoresistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (QOLIE 31)</measure>
    <time_frame>At 3 months ; At 6 months ; At 12 months</time_frame>
    <description>Impact of SAS treatment on the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression questionnaire (BECK)</measure>
    <time_frame>At 3 months ; At 6 months ; At 12 months</time_frame>
    <description>Impact of SAS treatment on anxiety and depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somnolence questionnaire (Epworth)</measure>
    <time_frame>At 3 months ; At 6 months ; At 12 months</time_frame>
    <description>Impact of SAS treatment on somnolence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive capacity questionnaire (MOCA)</measure>
    <time_frame>At 3 months ; At 6 months ; At 12 months</time_frame>
    <description>Impact of SAS treatment on cognitive capacity questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <condition>Epilepsies, Partial</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>AHI/h &lt; 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 &lt; AHI/h &lt; 30. Randomization group. Intervention : CPAP active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 &lt; AHI/h &lt; 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AHI/h &gt; 30. Intervention : CPAP active</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP active</intervention_name>
    <description>CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg</description>
    <arm_group_label>Group IIa</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP placebo</intervention_name>
    <description>CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.</description>
    <arm_group_label>Group IIb</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age ≥ 18.

          -  Patient suffering of pharmacoresistant epilepsy.

          -  Frequency of epilepsy crisis : minimum 4 per month.

          -  Antiepileptic drug on a stable dose for at least 2 months.

          -  SA-SDQ score ≥ 25.

          -  Written informed consent obtained.

          -  Patient affiliated with a social security regimen.

        Exclusion Criteria:

          -  Pregnant females (female subjects who are lactating are not excluded).

          -  Anterior CPAP treatment.

          -  Central apnea &gt;20% during the initial polysomnography.

          -  Mental retardation or severe cognitive impairment.

          -  Presence of pseudo-crisis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe DERAMBURE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe DERAMBURE, MD, PhD</last_name>
    <email>philippe.derambure@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Flavien Gautron, Study Co</last_name>
    <email>flavien.gautron@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Lille - Rue Emile LAINE - Hopitâl Roger Salengro Rez de Chaussée - Neurophysiologie Clinique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Derambure, MD PHU</last_name>
      <email>philippe.derambure@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Flavien Gautron, Study Co</last_name>
      <email>flavien.gautron@chru-lille.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CPAP</keyword>
  <keyword>Sleep Apnea Syndrome</keyword>
  <keyword>Pharmacoresistant Epilepsy</keyword>
  <keyword>Apnea Hypopnea-Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

